Advertisement
ABBV vs JNJ
ABBV vs JNJ: A Comprehensive Stock Comparison of AbbVie and Johnson & Johnson
Key Takeaways
- Johnson & Johnson (JNJ) has shown stronger year-to-date returns at approximately 47%, outpacing AbbVie's 33%, reflecting broader market momentum in diversified healthcare.
- AbbVie (ABBV) offers a higher dividend yield of around 3%, compared to JNJ's 2.5%, appealing to income-focused investors amid stable pharmaceutical demand.
- JNJ maintains a lower price-to-earnings ratio near 20, suggesting better value relative to AbbVie's elevated ratio above 170, influenced by acquisition-related costs.
- Recent market activity highlights JNJ's positive momentum with FDA approvals, contrasting AbbVie's partnership shifts and pipeline advancements amid sector-wide drug pricing discussions.
- Both stocks exhibit resilience in the healthcare sector, but JNJ's larger market cap of nearly $500 billion provides greater stability against volatility compared to AbbVie's $400 billion.
- Risk factors differ, with JNJ facing ongoing litigation pressures and ABBV navigating post-patent challenges for key drugs.
Introduction
AbbVie (ABBV) and Johnson & Johnson (JNJ) represent two prominent players in the pharmaceutical industry, making them suitable for side-by-side evaluation in a stock comparison. AbbVie, spun off from Abbott Laboratories in 2013, focuses on immunology, oncology, and neuroscience therapeutics, while Johnson & Johnson operates across innovative medicine and medtech segments following its consumer health spin-off. Investors and traders interested in healthcare stocks might compare them to assess relative performance, growth drivers, and risk exposure in the current market environment. This analysis highlights business contexts, recent momentum, and key contrasts, aiding decisions for long-term holders seeking dividends or growth-oriented portfolios amid evolving sector dynamics like regulatory changes and innovation pipelines.
ABBV Overview and Recent Performance
AbbVie Inc. (ABBV) is a research-driven biopharmaceutical company specializing in treatments for chronic conditions, with flagship products like Skyrizi for immunology and Vraylar for neuroscience. Its portfolio emphasizes high-margin specialty drugs, supported by a robust R&D pipeline. In recent weeks, ABBV stock has experienced modest fluctuations, trading near its 52-week high but showing a slight dip amid broader sector adjustments. Key influences include strategic partnership restructurings, such as with OSE Immunotherapeutics to prioritize advanced immunology assets, and participation in industry-wide drug pricing negotiations. Analyst sentiment remains positive, driven by forecasts of pipeline growth offsetting earlier patent expirations, with market cap around $403 billion and a forward focus on oncology advancements presented at recent conferences.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ) is a global healthcare leader with operations in pharmaceuticals and medical devices, known for oncology drugs like Darzalex and medtech innovations in orthopedics and surgery. Following the 2023 spin-off of its consumer health business, JNJ has streamlined its focus on high-growth areas. Over recent market activity, JNJ shares have demonstrated upward momentum, approaching 52-week highs with gains reflecting investor confidence in its diversified revenue streams. Notable developments include FDA approval for a subcutaneous version of its NSCLC drug Rybrevant, bolstering its oncology segment, though offset by litigation outcomes related to legacy products. With a market cap nearing $500 billion, sentiment is supported by consistent earnings beats and strategic investments, positioning it resiliently amid healthcare sector trends.
AI Trading Bot Perspective
Tickeron offers AI trading bots for both ABBV and JNJ, utilizing strategies like the Trend Trader for Beginners Strategy for Large-Cap Stocks (60-min TA) to analyze trends and support automated trading decisions.
Head-to-Head Comparison
In terms of business models, ABBV is more concentrated on biopharma innovation, deriving significant revenue from immunology (over 50%), while JNJ benefits from diversification across pharma (about 60%) and medtech, reducing exposure to single-segment risks. Growth drivers for ABBV center on next-generation drugs like Rinvoq, with recent pipeline data showcasing potential in blood cancers, whereas JNJ leverages medtech recovery and oncology expansions, including recent approvals enhancing its competitive edge. Recent momentum favors JNJ with a 3% monthly gain versus ABBV's 1% decline, attributed to JNJ's broader resilience amid economic shifts. Risk factors include ABBV's higher dependency on patent protections and elevated valuation metrics, contrasting JNJ's litigation vulnerabilities from talc cases, though mitigated by its scale. Sector exposure aligns both to healthcare tailwinds like aging populations, but JNJ's medtech arm provides buffer against pure pharma volatility. Market sentiment leans toward JNJ for stability, per analyst upgrades, while ABBV attracts for yield in income strategies.
Tickeron AI Verdict
Based on trend consistency and relative positioning, Tickeron's AI appears to favor JNJ over ABBV at present, as JNJ demonstrates stronger recent gains and a more attractive valuation amid stable catalysts like regulatory approvals, potentially offering better risk-adjusted returns in the near term.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and JNJ is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 5 FA rating(s) are green whileJNJ’s FA Score has 3 green FA rating(s).
- ABBV’s FA Score: 5 green, 0 red.
- JNJ’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while JNJ’s TA Score has 6 bullish TA indicator(s).
- ABBV’s TA Score: 5 bullish, 4 bearish.
- JNJ’s TA Score: 6 bullish, 3 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +0.22% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +3.48% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +6.56%, and the average quarterly price growth was +4.69%.
Reported Earning Dates
ABBV is expected to report earnings on Jul 24, 2026.
JNJ is expected to report earnings on Jul 15, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | JNJ | ABBV / JNJ | |
| Capitalization | 402B | 580B | 69% |
| EBITDA | 16.9B | 33.7B | 50% |
| Gain YTD | 1.303 | 17.682 | 7% |
| P/E Ratio | 111.63 | 27.91 | 400% |
| Revenue | 62.8B | 96.4B | 65% |
| Total Cash | 9.39B | 22.1B | 42% |
| Total Debt | 72.9B | 55B | 133% |
ABBV | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 32 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 11 | 10 | |
SMR RATING 1..100 | 1 | 36 | |
PRICE GROWTH RATING 1..100 | 33 | 45 | |
P/E GROWTH RATING 1..100 | 26 | 18 | |
SEASONALITY SCORE 1..100 | 3 | 55 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (11) in the Pharmaceuticals Major industry is in the same range as JNJ (13). This means that ABBV’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Profit vs Risk Rating (10) in the Pharmaceuticals Major industry is in the same range as ABBV (11). This means that JNJ’s stock grew similarly to ABBV’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for JNJ (36). This means that ABBV’s stock grew somewhat faster than JNJ’s over the last 12 months.
ABBV's Price Growth Rating (33) in the Pharmaceuticals Major industry is in the same range as JNJ (45). This means that ABBV’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's P/E Growth Rating (18) in the Pharmaceuticals Major industry is in the same range as ABBV (26). This means that JNJ’s stock grew similarly to ABBV’s over the last 12 months.
| ABBV | JNJ | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 37% | 1 day ago 29% |
| Stochastic ODDS (%) | 1 day ago 45% | 1 day ago 43% |
| Momentum ODDS (%) | 1 day ago 67% | 1 day ago 42% |
| MACD ODDS (%) | N/A | 1 day ago 33% |
| TrendWeek ODDS (%) | 1 day ago 60% | 1 day ago 43% |
| TrendMonth ODDS (%) | 1 day ago 62% | 1 day ago 46% |
| Advances ODDS (%) | 9 days ago 57% | 4 days ago 44% |
| Declines ODDS (%) | 3 days ago 48% | 12 days ago 42% |
| BollingerBands ODDS (%) | 1 day ago 33% | N/A |
| Aroon ODDS (%) | 1 day ago 65% | 1 day ago 45% |
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +1.32% | ||
| BMY - ABBV | 52% Loosely correlated | +0.40% | ||
| NVS - ABBV | 47% Loosely correlated | -0.55% | ||
| AMGN - ABBV | 45% Loosely correlated | +0.32% | ||
| MRK - ABBV | 42% Loosely correlated | -1.42% | ||
| JNJ - ABBV | 42% Loosely correlated | +1.07% | ||
More | ||||
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.